Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Notes Payables: 2010-2019

Historic Notes Payables for Arrowhead Pharmaceuticals (ARWR) over the last 8 years, with Sep 2019 value amounting to $2.7 million.

  • Arrowhead Pharmaceuticals' Notes Payables rose 1106.33% to $2.7 million in Q3 2019 from the same period last year, while for Sep 2019 it was $2.7 million, marking a year-over-year increase of 1106.33%. This contributed to the annual value of $2.7 million for FY2019, which is 1106.33% up from last year.
  • As of FY2019, Arrowhead Pharmaceuticals' Notes Payables stood at $2.7 million, which was up 1,106.33% from $223,820 recorded in FY2018.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Notes Payables peaked at $2.7 million during FY2019, and registered a low of $194,310 during FY2016.
  • For the 3-year period, Arrowhead Pharmaceuticals' Notes Payables averaged around $1.0 million, with its median value being $223,820 (2018).
  • Data for Arrowhead Pharmaceuticals' Notes Payables shows a peak YoY skyrocketed of 1,106.33% (in 2019) over the last 5 years.
  • Yearly analysis of 4 years shows Arrowhead Pharmaceuticals' Notes Payables stood at $194,310 in 2016, then climbed by 7.31% to $208,506 in 2017, then climbed by 7.34% to $223,820 in 2018, then spiked by 1,106.33% to $2.7 million in 2019.